RxDoctor Payments Data

Phyllis Tien

Infectious Disease · San Francisco, CANPI 1346358835

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Gilead at 57.6% of the total. Reporting peaked in 2023 at $170 and has fallen 64.0% since, to $61 in 2025.

$510in general payments, 2019–2025

Across 14 payments — averaging $36.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$294
  • Merck$198
  • Bavarian Nordic A/s$19
$798,050in research payments, 2019–2025

Across 14 payments — averaging $57,004 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$749K
  • Gilead$31K
  • Eli Lilly$18K

What the payments were for

  • Food & beverage$510100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead9$294
Merck4$198
Bavarian Nordic A/s1$19

How this compares

$510 in reported general payments places this provider in the 55th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Other infectious disease in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →